Abstract:To investigate the effect of 1α,25(OH)2D3 on hepatic
stellate cells and the mechanism of the TGF-β1/Smad signaling pathway.LX2 cells were treated with TGF-β1 and different concentrations of
1α,25(OH)2D3. Cell proliferation was assessed
using the CCK8 assay to determine the optimal concentration of
1α,25(OH)2D3 activity. The cell cycle and
apoptotic rates were evaluated using flow cytometry. The expressions of
Samd2, Samd3, Samd4, and Samd7 was assessed by western blotting, whereas the
expression of MMP1, MMP13, and TIMP-1 was detected by qPCR.Compared with the control group, the 1α,25(OH)2D3 group
had a higher apoptotic rate of LX2 cells, the cell cycle was blocked from
the G1 stage to the S stage, the expressions of Samd2, Samd7, MMP1, and
MMP13 increased, while the expressions of Samd3, Samd4, and TIMP-1
decreased.1α,25(OH)2D3 inhibits hepatic stellate cell activation
and exerts anti-hepatic fibrosis effects by downregulating the expression of
Samd3, Samd4, TIMP-1 and upregulating the expression of Samd2, Samd4, MMP1,
and MMP13.